Bausch+Lomb reported positive 24-month results from a pivotal US clinical trial evaluating the Elios system, an implant-free excimer laser procedure for reducing intraocular pressure (IOP) in patients with open-angle glaucoma.

The prospective, multicenter Excimer Laser Trabeculostomy Glaucoma Treatment Study enrolled 318 patients across 20 sites in the United States. Participants had mild to moderate primary open-angle glaucoma and cataracts and were using topical IOP-lowering medications at baseline. The trial evaluated 2 co-primary endpoints: the proportion of patients achieving at least a 20% reduction in unmedicated diurnal IOP and the mean change in IOP.

According to the company, both endpoints were met. At 24 months, 76% of patients achieved a reduction of 20% or greater in unmedicated diurnal IOP, with a mean decrease of 7.4 mmHg. In addition, 82% of patients were medication-free at 23 months.

No intraoperative complications were reported. Postoperative adverse events were described as similar to those observed with cataract surgery alone.

The Elios system uses excimer laser technology to enhance aqueous outflow without implantation of a device. The procedure is currently CE marked in Europe but remains investigational in the United States and has not been reviewed by the US Food and Drug Administration (FDA) for safety or efficacy.